Announced details
Anticancer drug for lymphoid hematologic malignancies
WHO has published the recommended INN (rINN) for the Company's development product CTX-177. Capital, personnel and business relationships: Not disclosed.
An international organization that deliberates and assigns International Nonproprietary Names (INNs) for medicines. Other information: Not disclosed.
International Nonproprietary Name (INN) / recommended INN (rINN)
World Health Organization (WHO)
Fujisawa, Kanagawa Prefecture (the company's head office)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
World Health Organization (WHO)
| Item | Details |
|---|---|
| Names of Products / Services Covered | ocipumaltib (development code: CTX-177) |
| Counterparty | World Health Organization (WHO) |
| Counterparty overview | An international organization that deliberates and assigns International Nonproprietary Names (INNs) for medicines. Other information: Not disclosed. |
| Relationship with the Company | WHO has published the recommended INN (rINN) for the Company's development product CTX-177. Capital, personnel and business relationships: Not disclosed. |
| Applicable area | Anticancer drug for lymphoid hematologic malignancies |
| Award/certification name | International Nonproprietary Name (INN) / recommended INN (rINN) |
| Awarding / certifying body | World Health Organization (WHO) |
| Location | Fujisawa, Kanagawa Prefecture (the company's head office) |
| Source | World Health Organization (WHO) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.We believe that the assignment of an INN marks another step forward in activities toward commercialization.